13 results on '"Gregory A. Broderick"'
Search Results
2. Small cell carcinoma of the prostate in an elderly patient: a case report and review of the literature
- Author
-
Dale Alan Whitaker Jr., Daniel H. Miller, Niveditha Jagadesh, Gerald W. Strong, Lauren Hintenlang, William B. Schenk, Gregory A. Broderick, Katherine S. Tzou, and Steven J. Buskirk
- Subjects
Small cell carcinoma ,Prostate cancer ,Radiotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy. Here we present the case of an elderly 89- year-old Caucasian male who was diagnosed with SCC of the prostate. Despite proceeding with a course of definitive radiotherapy, the patient experienced rapid progression of disease and ultimately elected to discontinue radiation therapy and receive hospice care.
- Published
- 2016
- Full Text
- View/download PDF
3. Orthotopic ureterocele masquerading as a bladder tumor in a woman with pelvic pain
- Author
-
David D. Thiel, Steven P. Petrou, and Gregory A. Broderick
- Subjects
bladder ,ureterocele ,bladder neoplasms ,ureteral calculi ,pelvic pain ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Single system orthotopic ureteroceles often present in adulthood are associated with characteristic radiographic findings. We present the case of a 54 year old woman with 8 months of urgency/frequency and pelvic pain that has the cystoscopic appearance of a bladder tumor. Cystoscopic images, radiographs and intraoperative photos demonstrate the work-up, evaluation, and treatment of this unique single system orthotopic ureterocele containing a calculus. This patient demonstrates the need for cystoscopy accompanied by upper tract imaging in patients with new onset pelvic pain, urgency/frequency, and frequent urinary tract infections.
- Published
- 2005
- Full Text
- View/download PDF
4. Restorative Therapies for Erectile Dysfunction: Position Statement From the Sexual Medicine Society of North America (SMSNA)
- Author
-
Gerald B. Brock, Kelvin P. Davies, James Liu, Trinity J. Bivalacqua, Ranjith Ramasamy, Andrew T. Gabrielson, John P. Mulhall, Run Wang, Landon Trost, Gregory A. Broderick, and Kevin Y. Chu
- Subjects
Position statement ,medicine.medical_specialty ,LiSWT, Low-intensity shock wave therapy ,Restorative therapies ,Stromal vascular fraction ,Urology ,Endocrinology, Diabetes and Metabolism ,030232 urology & nephrology ,Dermatology ,Disease ,IIEF, International Index of Erectile Function ,03 medical and health sciences ,Behavioral Neuroscience ,Other systems of medicine ,0302 clinical medicine ,Endocrinology ,Sexual medicine ,Medicine ,Society Report ,EHS, Erection Hardness Score ,Erectile dysfunction ,Intensive care medicine ,Adverse effect ,Stem cell therapy ,030219 obstetrics & reproductive medicine ,SVF, Stromal vascular fraction ,business.industry ,Outcome measures ,medicine.disease ,SHIM, Sexual Health Inventory for Men ,SCT, stem cell therapy ,Clinical trial ,Psychiatry and Mental health ,Reproductive Medicine ,ED, Erectile dysfunction ,PDE5i, phosphodiesterase type 5 inhibitor ,PRP, Platelet-rich plasma ,Platelet rich plasma ,business ,Sexual function ,Low intensity shock wave therapy ,RZ201-999 - Abstract
Introduction Current non-invasive treatments for erectile dysfunction (ED) include oral medications, intracavernosal injections, and vacuum-assisted devices. Though these therapies work well for many, a subset of patients have contraindications or are unsatisfied with these options. Restorative therapies for ED are a new frontier of treatments focused on regenerating diseased tissue and providing a potential “cure” for ED. Aim The aim of this position statement is to examine existing clinical trial data for restorative therapies and identify elements that require further research before widespread adoption. Methods A literature review was performed to identify all clinical trials performed with regenerative therapy for ED. This includes treatments such as stem cell therapy (SCT), platelet rich plasma (PRP), and restorative related technologies like low-intensity shockwave therapy (LiSWT). Main Outcome Measures Most clinical trials in restorative therapies were assessed for safety, feasibility, or efficacy. This included recording adverse events, changes in sexual function and erectile function questionnaires, and diagnostics measures. Results To date there is an absence of robust clinical data supporting the efficacy of restorative therapies regarding ED, though technologies such as LiSWT have established relative safety. Conclusions Restorative therapies are a promising technology that represents a new frontier of treatment geared towards reversing disease pathology rather than just treating symptoms. However, current published clinical studies are limited. Future work needs to be adequately powered, multi-center, randomized, sham/placebo-controlled trials in well-characterized patient populations to ensure safety and demonstrate efficacy. Until these studies are done, restorative therapies should be reserved for clinical trials and not offered in routine clinical practice.
- Published
- 2021
5. Multispecialty retrospective review of the clinical utility of pelvic magnetic resonance imaging in the setting of pelvic pain
- Author
-
Caroline Snowden, Gregory A. Broderick, Ram A. Pathak, Paul R. Young, John R Moore, and Candice W. Bolan
- Subjects
medicine.medical_specialty ,Urology ,Testicular pain ,Prostatitis ,Prostate magnetic resonance imaging (Prostate MRI) ,chronic pelvic pain ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,prostatitis ,medicine ,Rectal Pain ,Penile pain ,male pelvic pain ,business.industry ,Pelvic pain ,medicine.disease ,Reproductive Medicine ,030220 oncology & carcinogenesis ,Joint pain ,Original Article ,Radiology ,Diagnosis code ,medicine.symptom ,business ,Scrotal Pain - Abstract
Background: Pelvic pain is a common complaint, and management of it is often difficult. We sought to evaluate the utility of magnetic resonance imaging (MRI) in the diagnosis of male pelvic pain. Though MRIs are commonly ordered to evaluate pelvic pain, there are very few studies obtaining the efficacy of pelvic MRI in determining a definitive diagnosis. The primary aim of our study was to evaluate the clinical utility of pelvic MRI for a diagnosis code that included pain. Methods: After receiving institutional review board approval, a retrospective study was performed of all pelvic MRIs completed at our institution from January 2, 2010 to December 31, 2014. These were further delineated into ordering providers by specialty and urology-specific International Classification of Diseases, Ninth Revision (ICD-9) code diagnoses (male pelvic pain, prostatitis, groin pain, scrotal pain, testicular pain, and penile pain). Clinical utility was defined as positive if MRI findings resulted in a change in management. Subanalysis was performed on patients with an ICD-9 co-diagnosis of previous oncologic concern. Results: A total of 2,643 pelvic MRIs were ordered at our institution over a 5-year period. Of these, 597 pelvic MRIs (23%) were ordered for a diagnosis code that included pain (hip pain, rectal pain, joint pain, penile pain, scrotal pain, male pelvic pain and orchitis). Total utility for MRIs to find anatomic abnormalities potentially responsible for the present pain was 34% (205/597). When ordered by urologic providers, utility was 23%. Oncologists represented the highest positivity rate at 57%. Conclusions: Chronic pelvic pain is a multispecialty complaint that is difficult to treat. We were surprised to find the large number of both specialists and generalists invested in the management of pelvic pain. The increasing availability of MRI technology makes it a likely candidate to test for a clinically significant anatomic reason for pain. Though MRI is a test with minimal adverse effect and no increased risk of radiation exposure, the cost on the healthcare system should be offset by a clear clinical utility. We found total utility to be 34% across all ordering providers and an increase in positivity with concern of oncologic disease. Therefore, we would recommend pelvic MRIs in the evaluation of patients with refractory pelvic pain.
- Published
- 2017
6. Survivorship, Version 2.2018: Clinical Practice Guidelines in Oncology
- Author
-
Deborah A. Freedman-Cass, Electra D. Paskett, Allison A. King, Sophia K. Smith, Allison L. McDonough, Kathryn J. Ruddy, Phyllis C. Zee, Debra L. Friedman, Divya Koura, Jose G. Montoya, Javid Moslehi, Gregory A. Broderick, Crystal S. Denlinger, Nicole R. McMillian, Robin M. Lally, Susan G. Urba, Melissa M. Hudson, Wendy Demark-Wahnefried, Tara Sanft, Kathi Mooney, Karen L. Syrjala, Tracey O'Connor, Terry S. Langbaum, Mindy Goldman, William F. Pirl, Paula Silverman, Michelle E. Melisko, Mark T. Wakabayashi, Nazanin Khakpour, Amye J. Tevaarwerk, Jeffrey Peppercorn, K. Scott Baker, M. Alma Rodriguez, and Linda Overholser
- Subjects
medicine.medical_specialty ,MEDLINE ,Survivorship ,030204 cardiovascular system & hematology ,Medical Oncology ,Risk Assessment ,Article ,03 medical and health sciences ,Immunocompromised Host ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Cancer Survivors ,Survivorship curve ,Neoplasms ,medicine ,Humans ,Mass Screening ,Anthracyclines ,Lymphedema ,Societies, Medical ,Cardiotoxicity ,Antibiotics, Antineoplastic ,business.industry ,Vaccination ,Cancer ,Bacterial Infections ,medicine.disease ,humanities ,United States ,Cancer treatment ,Clinical Practice ,Oncology ,Virus Diseases ,030220 oncology & carcinogenesis ,Family medicine ,business ,Psychosocial - Abstract
The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for common physical and psychosocial consequences of cancer and cancer treatment to help healthcare professionals who work with survivors of adult-onset cancer in the posttreatment period. This portion of the guidelines describes recommendations regarding the management of anthracycline-induced cardiotoxicity and lymphedema. In addition, recommendations regarding immunizations and the prevention of infections in cancer survivors are included.
- Published
- 2018
7. Small Cell Carcinoma of the Prostate in an Elderly Patient: A Case Report and Review of the Literature
- Author
-
William B. Schenk, Gerald Strong, Gregory A. Broderick, Steven J. Buskirk, L. Hintenlang, Niveditha Jagadesh, Dale Alan Whitaker, Katherine S. Tzou, and Daniel H. Miller
- Subjects
Oncology ,medicine.medical_specialty ,Histology ,medicine.medical_treatment ,030232 urology & nephrology ,Case Report ,Malignancy ,Small-cell carcinoma ,lcsh:RC254-282 ,Androgen deprivation therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Internal medicine ,medicine ,Carcinoma ,Small cell carcinoma ,Radiotherapy ,business.industry ,Prostatectomy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Radiation therapy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business - Abstract
Prostate cancer is the most common malignancy of men in the United States. Small-cell carcinoma (SCC), which typically presents as an aggressive lung malignancy, is a rare diagnosis within the setting of prostate cancer pathology. Due to its limited prevalence, little information regarding the treatment and prognosis of this disease in large populations is available. To date our current knowledge base is largely limited to case reports and retrospective case reviews. The mainstay of treatment for this particular histology most often involves a multimodality approach utilizing chemotherapy in conjunction with radiation therapy, androgen deprivation therapy, or prostatectomy. Here we present the case of an elderly 89-year-old Caucasian male who was diagnosed with SCC of the prostate. Despite proceeding with a course of definitive radiotherapy, the patient experienced rapid progression of disease and ultimately elected to discontinue radiation therapy and receive hospice care.
- Published
- 2016
8. Oral Pharmacotherapy for Male Sexual Dysfunction : A Guide to Clinical Management
- Author
-
Gregory A. Broderick and Gregory A. Broderick
- Subjects
- Impotence, Impotence--Chemotherapy, Cyclic nucleotide phosphodiesterases--Inhibitors--Therapeutic use
- Abstract
For the generation that reached sexual maturity in the 1960s, the “pill” became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought “this will change everything” and it clearly has—changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis) and vardenafil (Levitra), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.
- Published
- 2005
9. Low Intensity Shock Wave Therapy in the Management of Erectile Dysfunction
- Author
-
Gregory A. Broderick, Principal Investigator
- Published
- 2024
10. CHAPTER 1: THE MANAGEMENT OF ERECTILE DYSFUNCTION: AN AUA UPDATE.
- Author
-
DROGO K MONTAGUE, JONATHAN P JAROW, GREGORY A BRODERICK, ROGER R DMOCHOWSKI, JEREMY P HEATON, TOM F LUE, AARON J MILBANK, AJAY NEHRA, and IRA D SHARLIP
- Published
- 2005
- Full Text
- View/download PDF
11. PRP for the Treatment of Erectile Dysfunction (ED)
- Author
-
Gregory A. Broderick, Principal Investigator
- Published
- 2023
12. Comparison of patient-reported quality of life outcome questionnaire response rates between patients treated surgically for renal cell carcinoma and prostate carcinoma
- Author
-
Andrew J. Davidiuk, Nancy N. Diehl, Gregory A. Broderick, Andrea Tavlarides, Kaitlynn Custer, Michelle Arnold, Alexander S. Parker, and David D. Thiel
- Subjects
Oncology ,Quality of life ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Urology ,urologic and male genital diseases ,Nephrectomy ,Prostate cancer ,Renal cell carcinoma ,Internal medicine ,Surveys and Questionnaires ,medicine ,Partial nephrectomy ,Humans ,Registries ,Carcinoma, Renal Cell ,Aged ,Retrospective Studies ,Renal cell cancer ,Prostatectomy ,business.industry ,Cancer ,Prostatic Neoplasms ,Retrospective cohort study ,General Medicine ,medicine.disease ,Kidney Neoplasms ,female genital diseases and pregnancy complications ,Oncology outcomes ,Exact test ,Treatment Outcome ,Reproductive Medicine ,Florida ,Female ,business ,Research Article - Abstract
Background We sought to examine differences in response rates to quality of life (QoL) surveys in patients treated surgically for renal cell carcinoma (RCC) and prostate cancer (PCa) and to analyze factors associated with non-response of the surveys. Methods Patients who underwent surgery for RCC or PCa between 2006 and 2012 were offered enrollment in respective prospective cancer registries that included baseline and annual QoL assessments. We identified 201 RCC patients and 616 PCa patients who completed a baseline QoL survey and were mailed annual QoL surveys [RCC: SF-36, FACT–G (73 questions), PCa: EPIC, IIEF, Max-PC (80 questions)]. We compared patient characteristics between responders and non-responders using a Wilcoxon rank-sum test for continuous variables and a Fisher’s Exact test for categorical variables. Results The overall response rates for the PCa and RCC groups were 63 and 48 % (p
- Full Text
- View/download PDF
13. Current and future standards in evaluation of erectile dysfunction
- Author
-
Raymond W Pak and Gregory A Broderick
- Subjects
Erectile dysfunction ,evaluation ,vascular testing ,Diseases of the genitourinary system. Urology ,RC870-923 - Abstract
Sexual dysfunction and more specifically erectile dysfunction (ED) can be a harbinger of serious occult medical conditions. ED can be considered a clinical manifestation of generalized vascular disease and therefore shares similar risk factors: aging, hypertension, diabetes mellitus, hypercholesterolemia and smoking. The initial evaluation of men with ED should be thorough. Studies of normal and abnormal penile tumescence have led to the discovery of many important pathways. The greatest medical advance in the management of male sexual dysfunction since the identification of androgens have been the discoveries that nitric oxide (NO) is the primary neuro-modulator of penile smooth muscle relaxation and that oral phosphodiesterase type 5 inhibitors enhance erection quality through the NO mechanism. As a consequence of oral pharmacotherapies, the role of invasive diagnostics has diminished. Most guidelines recommend only history, physical exam and limited laboratory testing prior to instituting oral therapies for ED. In 2006 we still have unanswered questions about ED and these will frame the role of future diagnosis and therapy: can lifestyle changes alone improve erectile function; is ED a marker for the development of atherosclerotic heart disease, do lower urinary tract symptoms of benign prostatic hypertrophy and ED share a common pathway?
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.